Mark C. Schneyer, EVP and Chief Financial Officer of ACADIA Pharmaceuticals Inc., filed a Form 4 on October 30, 2026, disclosing two transactions in the company's common stock: a performance stock unit vesting on October 15, 2026, and a mandatory tax-withholding sale on October 30, 2026.

Key Highlights

  • Acquisition: Schneyer acquired 6,815 shares of common stock on October 15, 2026, upon vesting of performance stock units (PSUs), at a price of $0.
  • Disposal: Schneyer disposed of 3,321 shares on October 30, 2026, at a price of $20.88 per share, to cover tax withholding obligations.
  • Remaining ownership: Following both transactions, Schneyer directly beneficially owns 71,322 shares of ACADIA common stock.
  • PSU history: According to the filing, the October 15, 2026 vesting represents an incremental 25% of target from a PSU grant dated May 1, 2023, and together with prior vestings on August 16, 2024, and September 12, 2025, the PSUs have vested at 100% of target.
  • Rule 10b5-1: The filing states the mandatory sale was intended to comply with Rule 10b5-1(c)(1)(i)(B) under the Exchange Act.

ACADIA CFO Schneyer Reports PSU Vesting and Mandatory Tax Sale

According to the Form 4 filed with the SEC on October 30, 2026, Mark C. Schneyer, Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), reported two transactions in the company's common stock. On October 15, 2026, Schneyer acquired 6,815 shares through the vesting of performance stock units originally granted on May 1, 2023. The acquisition was coded as "A" and carried a price of $0, consistent with a standard PSU vesting event.

The filing explains that this October 15, 2026 vesting represents an incremental 25% of target, and that combined with earlier vestings on August 16, 2024, and September 12, 2025, the performance stock units have now vested at 100% of their target. Following the acquisition, Schneyer's directly held beneficial ownership stood at 74,643 shares before the second transaction.

On October 30, 2026, Schneyer disposed of 3,321 shares at a price of $20.88 per share, reducing his direct beneficial ownership to 71,322 shares. The filing characterizes this sale as mandatory, stating it "was made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units." The filing further states that the sale was intended to comply with, and be interpreted to meet, the requirements of Rule 10b5-1(c). The Form 4 was signed by Jennifer J. Rhodes as Attorney-in-Fact on October 30, 2026.

What Was Disclosed

ACADIA Pharmaceuticals CFO Mark C. Schneyer disclosed a PSU vesting of 6,815 shares on October 15, 2026, and a mandatory tax-withholding sale of 3,321 shares at $20.88 on October 30, 2026, leaving him with direct beneficial ownership of 71,322 shares.